Quince Therapeutics Inc

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “With the acquisition of EryDel S.p.A. in October last year, we have successfully shi.

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

XBiotech

Two microcap biotech stocks to consider for the science-challenged among us.

Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. “We are pleased to announce the formation of our Scientific Advisor.

Quince Therapeutics Launches Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. “We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's calib.

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 14, 2024 beginning at 10:40 a.

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San Francisco, California in January 2024: 7th Annual Neuroscience Innovation Forum (NIF) – Sun.

Quince Therapeutics to Participate at Investor Events in January 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince's newly acquired Phase 3 lead asset, EryDex, targets a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). Current.

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the partial clinical hold on EryDel S.p.A's Investigational New Drug (IND) application for its lead Phase 3 asset, EryDex. Pending the closing of Quince's acquisition of EryDel, Quince.

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, announced that Dirk Thye, M.D., the company's Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time). A live webcast of the investor presentation will be accessible on th.

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the company has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments. EryDel has developed an autologous intracellular drug enc.

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Offers $1.80 per share in cash plus CVR to receive 85% of the future net proceeds Quince receives as part of the Lighthouse Pharmaceuticals transaction Stock trades below its net cash and investments balance of approximately $2.30 per share Willing to increase cash component of the offer if company can demonstrate that its net cash at closing would be higher than we currently estimate Offer's cash component alone represents 115% premium to company's stock price before our original buyout offer in March NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Earlier today Echo Lake Capital issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX). The letter described a revised proposal to acquire all the company's common stock for $1.80 per share in cash plus a CVR to receive 85% of the future net proceeds received from the Lighthouse Pharmaceutical transaction announced on January 27, 2023.

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

- Criticizes Board's abysmal track record, excessive compensation, and limited stock ownership - Calls on Board to abandon any potential acquisitions and instead to liquidate/sell the company - Notes stock dropped 75% after company's last acquisition (a related party transaction) - Stock trades at approximately 60% of its net cash - Closing company would be easy and inexpensive - Stock trades below rejected buyout offer of $1.60 per share - Stock is heavily shorted despite trading significantly below cash (32 days to cover) - Cautions Board not to repeat mistake it made last year of not selling/liquidating the company NEW YORK, NY / ACCESSWIRE / June 6, 2023 / Earlier today Echo Lake Capital issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX). The letter criticized the Board's poor investment decisions, excessive compensation, and lack of stock ownership during a time that significant shareholder value was destroyed.

Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash.

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that it has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support Quince's Board of Directors and management team in the review and evaluation of strategic alternatives intended to maximize long-term value for all Quince stockholders.

Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc.

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Cerberus Cyber Sentinel Corp

Novo Integrated Sciences, Inc.

Here's how to understand what components drive value with penny stocks The post The Anatomy of Penny Stocks: Understanding What Drives Value appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Anatomy of Penny Stocks: Understanding What Drives Value

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital.

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Offers $1.60 per share in cash Offer represents 90% premium to yesterday's closing price Stock currently trades below its current cash and investments balance of $2.55 per share Company also has other assets including earnouts and NOLs Company is not developing or selling any drugs Offer not contingent on outside financing NEW YORK, NY / ACCESSWIRE / March 21, 2023 / Earlier today Echo Lake Capital issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX). The letter described a proposal to acquire all the company's common stock for $1.60 per share in cash.

Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today provided an update on the company's development pipeline and business outlook for 2023. The company intends to prioritize capital resources toward the expansion of its development pipeline through opportunistic in-licensing and acquisition of clinical-stage assets targeting debilitating and rare diseases. Quince plans to out-license its bone-targeting drug platform and precision bone growth molecule NOV004 designed for accelerated fracture repair in patients with bone fractures and osteogenesis imperfecta.

Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

Nikola

Opendoor

Use these tips for finding penny stocks to buy The post How to Identify Potentially Profitable Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Identify Potentially Profitable Penny Stocks to Buy

Quince Therapeutics (NASDAQ: QNCX ) stock is rocketing higher on Friday after completing an asset sale to Lighthouse Pharmaceuticals. This sale covers the company's legacy small molecule protease inhibitor portfolio.

Why Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company's legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, former chief executive officer of Quince's predecessor company Cortexyme.

Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company's participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a poster showcasing the broad applicability of the company's highly

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company's participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the

Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

News for Quince Therapeutics Inc Stock (QNCX)